{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T20:28:16Z","timestamp":1747168096144,"version":"3.40.5"},"reference-count":22,"publisher":"JLE","issue":"7","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T00:00:00Z","timestamp":1670025600000},"content-version":"am","delay-in-days":367,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["N\u00e9phrologie & Th\u00e9rapeutique"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.nephro.2021.05.004","type":"journal-article","created":{"date-parts":[[2021,7,3]],"date-time":"2021-07-03T20:47:27Z","timestamp":1625345247000},"page":"543-546","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Chronic kidney disease consecutive to chemotherapy for chondroblastic osteosarcoma: A report on 6 pediatric cases"],"prefix":"10.1684","volume":"17","author":[{"given":"Alice","family":"Paul","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anita","family":"Duncan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justine","family":"Bacchetta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurence","family":"Dubourg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Perrine","family":"Marec-B\u00e9rard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3050-8898","authenticated-orcid":false,"given":"Corentin","family":"Tann\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"18929","reference":[{"key":"10.1016\/j.nephro.2021.05.004_bib0115","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/pbc.20228","article-title":"High-dose ifosfamide in relapsed pediatric osteosarcoma: therapeutic effects and renal toxicity","volume":"44","author":"Berrak","year":"2005","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.nephro.2021.05.004_bib0120","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/cncy.21715","article-title":"Chondroblastic osteosarcoma: Cytomorphologic characteristics and differential diagnosis on FNA","volume":"124","author":"VandenBussche","year":"2016","journal-title":"Cancer Cytopathol"},{"key":"10.1016\/j.nephro.2021.05.004_bib0125","doi-asserted-by":"crossref","first-page":"11","DOI":"10.11604\/pamj.2017.27.11.12418","article-title":"Chondroblastic osteosarcoma of the distal tibia: a rare case report","volume":"27","author":"Fredj","year":"2017","journal-title":"Pan Afr Med J"},{"key":"10.1016\/j.nephro.2021.05.004_bib0130","first-page":"1636","article-title":"Risk factors for nephrotoxicity after ifosfamide treatment in children: a UKCCSG Late Effects Group study. United Kingdom Children's Cancer Study Group","volume":"82","author":"Skinner","year":"2000","journal-title":"Br J Cancer"},{"key":"10.1016\/j.nephro.2021.05.004_bib0135","doi-asserted-by":"crossref","first-page":"5350","DOI":"10.1200\/JCO.2008.17.5257","article-title":"Long-term evaluation of Ifosfamide-related nephrotoxicity in children","volume":"27","author":"Oberlin","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.nephro.2021.05.004_bib0140","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1016\/j.ejca.2012.03.009","article-title":"Long term renal toxicity of ifosfamide in adult patients--5 year data","volume":"48","author":"Farry","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.nephro.2021.05.004_bib0145","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.clon.2006.11.003","article-title":"Ifosfamide encephalopathy","volume":"19","author":"Ajithkumar","year":"2007","journal-title":"Clin Oncol"},{"issue":"Suppl 2","key":"10.1016\/j.nephro.2021.05.004_bib0150","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1159\/000073351","article-title":"Side effects of ifosfamide","volume":"65","author":"Klastersky","year":"2003","journal-title":"Oncology"},{"key":"10.1016\/j.nephro.2021.05.004_bib0155","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/mpo.2950230403","article-title":"Failure of granulocyte-macrophage colony-stimulating factor to reduce febrile neutropenia in children with recurrent solid tumors treated with ifosfamide, carboplatin, and etoposide chemotherapy","volume":"23","author":"Marina","year":"1994","journal-title":"Med Pediatr Oncol"},{"key":"10.1016\/j.nephro.2021.05.004_bib0160","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/BF00292414","article-title":"Severe renal failure following high-dose ifosfamide and mesna","volume":"23","author":"Willemse","year":"1989","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.nephro.2021.05.004_bib0165","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1093\/ckj\/sfz183","article-title":"Ifosfamide nephrotoxicity in adult patients","volume":"13","author":"Ensergueix","year":"2019","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.nephro.2021.05.004_bib0170","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S0140-6736(96)03480-0","article-title":"Risk factors for ifosfamide nephrotoxicity in children","volume":"348","author":"Skinner","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.nephro.2021.05.004_bib0175","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1111\/bcp.13388","article-title":"Renal toxicity and chemotherapy in children with cancer","volume":"83","author":"Ruggiero","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.nephro.2021.05.004_bib0180","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/fcp.12345","article-title":"Possible role of CYP2B6 genetic polymorphisms in ifosfamide-induced encephalopathy: report of three cases","volume":"32","author":"Duflot","year":"2018","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.nephro.2021.05.004_bib0185","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1177\/009127009903900504","article-title":"Risk factors for long-term outcome of ifosfamide-induced nephrotoxicity in children","volume":"39","author":"Loebstein","year":"1999","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.nephro.2021.05.004_bib0190","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00467-017-3662-z","article-title":"Late renal toxicity of treatment for childhood malignancy: risk factors, long-term outcomes, and surveillance","volume":"33","author":"Skinner","year":"2018","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.nephro.2021.05.004_bib0195","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1056\/NEJMsa060185","article-title":"Chronic health conditions in adult survivors of childhood cancer","volume":"355","author":"Oeffinger","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2021.05.004_bib0200","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1681\/ASN.2008030287","article-title":"New equations to estimate GFR in children with CKD","volume":"20","author":"Schwartz","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2021.05.004_bib0205","doi-asserted-by":"crossref","first-page":"e1001979","DOI":"10.1371\/journal.pmed.1001979","article-title":"Comparison of the Schwartz and CKD-EPI equations for estimating glomerular filtration rate in children, adolescents, and adults: A retrospective cross-sectional study","volume":"13","author":"Selistre","year":"2016","journal-title":"PLoS Med"},{"key":"10.1016\/j.nephro.2021.05.004_bib0210","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/S1470-2045(16)30096-1","article-title":"Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial","volume":"17","author":"Piperno-Neumann","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.nephro.2021.05.004_bib0215","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.nephro.2004.12.001","article-title":"[Anticancer drug-induced nephrotoxicity]","volume":"1","author":"Isnard-Bagnis","year":"2005","journal-title":"Nephrol Ther"},{"key":"10.1016\/j.nephro.2021.05.004_bib0220","first-page":"06","article-title":"[Swedish National Guidelines for long-term follow-up of childhood cancer survivors]","volume":"113","author":"Jarfelt","year":"2016","journal-title":"Lakartidningen"}],"container-title":["N\u00e9phrologie & Th\u00e9rapeutique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1769725521001358?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1769725521001358?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.jle.com\/10.1016\/j.nephro.2021.05.004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T16:21:35Z","timestamp":1741191695000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1769725521001358"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":22,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S1769725521001358"],"URL":"https:\/\/doi.org\/10.1016\/j.nephro.2021.05.004","relation":{},"ISSN":["1769-7255"],"issn-type":[{"type":"print","value":"1769-7255"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chronic kidney disease consecutive to chemotherapy for chondroblastic osteosarcoma: A report on 6 pediatric cases","name":"articletitle","label":"Article Title"},{"value":"N\u00e9phrologie & Th\u00e9rapeutique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nephro.2021.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Soci\u00e9t\u00e9 francophone de n\u00e9phrologie, dialyse et transplantation. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}